Drug Profile
Ulipristal - Boryung Pharmaceutical
Alternative Names: BR-UPSLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antineoplastics; Norpregnadienes; Oral contraceptives; Small molecules
- Mechanism of Action Selective progesterone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Uterine leiomyoma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Uterine-leiomyoma in South Korea (PO, Tablet)
- 09 Aug 2017 Boryung Pharmaceutical withdraws a phase I trial prior to enrolment due to problem of investigational products in healthy volunteers in South Korea (PO) (NCT03156127)
- 25 May 2017 Boryung Pharmaceutical plans a phase I trial in healthy volunteers in South Korea (NCT03156127)